Literature DB >> 367414

Cinnarizine in the treatment of chronic asthma.

M B Emanuel, J A Chamberlain, S Whiting, B G Rigden, A H Craven.   

Abstract

1 Cinnarizine, an inhibitor of calcium ion transport across smooth muscle cell membrane, has been shown to exert an anti-asthmatic effect in patients with chronic asthma. 2 It is postulated that antagonism to calcium ion transport across the mast cell membrane may cause the compound to have a pharmacological effect similar to sodium cromoglycate. 3 Cinnarizine is orally active and its therapeutic effect is demonstrated in a double-blind, cross-over, placebo controlled study. 4 Patient benefit was shown by a significant improvement in peak flow rate. A non-significant trend towards a reduction in symptomatic bronchodilator usage and a decrease in asthma symptom score was also shown. 5 It is concluded that cinnarizine could well prove to be the first of a new family of anti-asthmatic drugs offering a protective effect when taken systemically.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 367414      PMCID: PMC1429430          DOI: 10.1111/j.1365-2125.1979.tb00920.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  EXPIRATORY PEAK FLOW RATE. STANDARD VALUES FOR NORMAL SUBJECTS. USE AS A CLINICAL TEST OF VENTILATORY FUNCTION.

Authors:  G C LEINER; S ABRAMOWITZ; M J SMALL; V B STENBY; W A LEWIS
Journal:  Am Rev Respir Dis       Date:  1963-11

2.  EFFECTS OF COMPOUND 48/80, CHYMOTRYPSIN AND ANTI-SERUM ON ISOLATED MAST CELLS UNDER AEROBIC AND ANAEROBIC CONDITIONS.

Authors:  K SAEKI
Journal:  Jpn J Pharmacol       Date:  1964-09

3.  Human bioassay of antihistaminic agents.

Authors:  P E SIEGLER; T BODI; M A GERSHENFELD; E B BROWN; A D DUCANES; J H NODINE
Journal:  Ann Allergy       Date:  1962-01

4.  Maximum forced expiratory flow rate as a measure of ventilatory capacity: with a description of a new portable instrument for measuring it.

Authors:  B M WRIGHT; C B McKERROW
Journal:  Br Med J       Date:  1959-11-21

5.  Further observations on the disruption of rat mesentery mast cells caused by compound 48/80, antigen-antibody reaction, lecithinase A and decylamine.

Authors:  B HOGBERG; B UVNAS
Journal:  Acta Physiol Scand       Date:  1960-03-18

6.  Cinnarizine in the treatment of peripheral vascular disease: mechanisms related to its clinical action.

Authors:  M B Emanuel; J A Will
Journal:  Proc R Soc Med       Date:  1977

7.  Measurement of pain.

Authors:  E C Huskisson
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

8.  Role of contractile microfilaments in the release of histamine from mast cells.

Authors:  T S Orr; D E Hall; A C Allison
Journal:  Nature       Date:  1972-04-14       Impact factor: 49.962

9.  Comparison of peak flow gauge and peak flow meter.

Authors:  A Bhoomkar; S Davies; M Greary; E Hills
Journal:  Thorax       Date:  1975-04       Impact factor: 9.139

Review 10.  Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1974       Impact factor: 9.546

View more
  4 in total

1.  Efficacy of calcium channel blockers as maintenance therapy for asthma.

Authors:  Mary Ann Twiss; Eloise Harman; Sarah Chesrown; Leslie Hendeles
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 2.  Calcium channel blockers and asthma.

Authors:  S Y So; M Ip; W K Lam
Journal:  Lung       Date:  1986       Impact factor: 2.584

3.  Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma.

Authors:  D O Williams; P J Barnes; H P Vickers; M Rudolf
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-01

Review 4.  Recent advances in delivery systems and therapeutics of cinnarizine: a poorly water soluble drug with absorption window in stomach.

Authors:  Smita Raghuvanshi; Kamla Pathak
Journal:  J Drug Deliv       Date:  2014-11-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.